Swiss drugmaker Roche Holding AG has agreed to pay $137 per share to buy the rest of Foundation Medicine (FMI) , a $2.4 billion transaction that values the U.S. genomic profiling group at $5.3 billion, the partners said.
Swiss drugmaker Roche Holding AG has agreed to pay $137 per share to buy the rest of Foundation Medicine (FMI) , a $2.4 billion transaction that values the U.S. genomic profiling group at $5.3 billion, the partners said.
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
Reageer